<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50404">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081729</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0107</org_study_id>
    <nct_id>NCT02081729</nct_id>
  </id_info>
  <brief_title>Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)</brief_title>
  <official_title>Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KAIST</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      VZV is one of the important opportunistic infection in transplant recipients.Until now,
      there is no laboratory method to stratify the risk of VZV reactivation after solid organ
      transplantation. Theoretically, VZV-specific cell-mediate immune response before solid organ
      transplantation will further categorize the patients into high or low risk of VZV
      development after solid organ transplantation. The investigators thus evaluate the
      usefulness of VZV-specific ELISPOT assay in kidney transplant candidates to predict the
      development of VZV infection after kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will develop VZV-specific ELISPOT assay, then perform this assay before transplantation.
      We will evaluate whether this assay will predict zoster reactivation after transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>zoster development</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">181</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>high VZV ELISPOT results</arm_group_label>
    <description>high spot counts in ELISPOT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low VZV ELISPOT results</arm_group_label>
    <description>low spot counts in ELISPOT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Kindeny transplant recipients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 16 years or more

          -  agree with written informed consent

          -  WBC count 2000/uL or more

        Exclusion Criteria:

          -  no exclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Han Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung-Han Kim, MD</last_name>
    <phone>82-2-3010-3305</phone>
    <email>kimsunghanmd@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Han Kim, MD</last_name>
      <phone>82-2-3010-3305</phone>
      <email>kimsunghanmd@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sung-Han Kim</investigator_full_name>
    <investigator_title>Assocaite Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
